Skeletal myoblast sources compared: primary, iPSC-derived and immortalised

The short answer: the three routes are not competing products, they are three different trade-offs, and the price ranking is the opposite of the usefulness ranking for most projects. iPSC-derived myoblasts are the only human route with published catalogue prices you can act on today. Primary human myoblasts are the biologically appropriate input and are almost entirely quote-gated. Immortalised lines are the cheapest and the least human-relevant.

The single most consequential number in this comparison is not a price. It is that primary human myoblasts ship with a finite number of population doublings and exactly one supplier publishes the passage they ship at. Everything else is negotiable; that is arithmetic.

The three routes side by side

Route one: primary human myoblasts

This is the biologically correct input for almost any claim about human muscle, and it is the hardest to buy.

Cook MyoSite is the strongest capability and publishes no price at all. Their skMDC product line is characterised by age, sex, race and BMI, with diabetes history and physical activity available on request and a published Rare Disease Donor Guide. Lots are explicitly single-donor. The purity specification is ≥70 percent desmin-positive by immunocytology and/or flow cytometry of desmin and myosin heavy chain, and there is a separate CD56-positive product enriched to greater than 90 percent purity by immunomagnetic selection.

Two details make them the reference supplier in this category despite the price opacity. First, the CD56-selected product is the only actively selected human muscle cell product we found, rather than one that is merely characterised after the fact. Second, every lot must pass a differentiation test before release, with an explicit and honest carve-out for donors whose clinical condition may affect that ability. That carve-out is a supplier declining to over-promise on a rare disease donor, which is the correct behaviour and rarely seen.

Behind the catalogue sits contract capability: muscle and other adherent cell production, cryopreservation at any scale, manufacturing process development, procurement and processing from specific donor populations, custom media formulations, and QC analytical testing and assay development, backed by more than twenty years in muscle-derived cell therapy and phase-appropriate GMP manufacturing. If your programme needs GMP-grade myogenic cells, this is the route, and it is a programme rather than a purchase.

PromoCell is the price anchor. $1,124 for more than 500,000 viable cells after thawing, from adult single donors, with lot-specific source information available on request and HLA-typed donors available. Their characterisation is the one worth copying: per-lot immunohistochemistry testing sarcomeric myosin positivity and the absence of contaminating populations — smooth muscle α-actin negative, von Willebrand factor and Factor VIII-related antigen negative. Fibroblast and smooth muscle overgrowth is the classic failure mode in primary muscle culture, and a supplier that tests for what should not be there is telling you more than one that only tests for what should. Growth performance is tested through multiple passages to more than 15 population doublings without antibiotics, and lots are tested negative for HIV-1/2, HBV, HCV, HTLV-1/2, fungi, bacteria and mycoplasma.

Lonza publishes the number nobody else does. Clonetics HSMM CC-2580 ships cryopreserved in second passage and proliferating in third passage, guaranteed through 10 population doublings. That single disclosure is worth more than it looks. A vial at passage 2 with 10 guaranteed doublings ahead of it is a materially different product from a vial at passage 5, even when both are described as “human skeletal myoblasts”. Two operational consequences follow: ask every supplier for passage at ship in writing, and count your expansion budget in doublings rather than in flasks. If you spend three doublings expanding before you cast tissue, you have spent a third of the product.

The Lonza guarantee is conditional — it holds only if their SkGM-2 media and recommended protocols are used. That is a common structure and it is a real constraint if you run a house medium.

iXCells sells primary human myoblasts, satellite cells and skeletal muscle cells with no price at all. On a live query of their public store API, primary HSkMM, HSkMSC satellite cells and HSkMC all return zero, which on that platform means the SKU routes to contact rather than being free. Their iPSC-derived range on the same storefront is fully priced. That contrast, inside one supplier, is the clearest single illustration of where the quote-only wall sits in this market.

Route two: iPSC-derived myogenic cells

This route trades donor authenticity for reproducibility, and it is the only human route with catalogue prices you can plan a budget from today.

iXCells lists iPSC-derived normal myoblasts at $1,076 and the SOD1 A4V homozygous variant at $1,489, with dedicated expansion medium at $360 and differentiation medium at $149 sold separately. The media is not optional if you want the datasheet performance, and at $509 for the pair it is nearly half the cost of the cells again.

bit.bio is the deepest disease offer. ioSkeletal Myocytes are $1,198 for two vials of more than 2.5 million viable cells each, or $2,398 for two of more than 5 million — the same 240 per million at both tiers, so the large pack buys convenience rather than savings. The DMD exon 44, 45, 51 and 52 deletion lines are $1,558 and $3,118 at the two pack sizes, against a genetically matched wild-type control from the same supplier. That pairing is difficult to assemble any other way and it is the strongest argument for this route in dystrophy work. They report contractile, striated, multinucleated myocytes by day 10 post-revival, expression of desmin, dystrophin, titin and GLUT4, spontaneous synchronised calcium waves, and contraction in response to acetylcholine, with pharmacological validation in both directions — inhibition with the myosin-II ATPase inhibitor BDM and increased contractility with caffeine. For 3D work they report muscle bundles with twitch and tetanic forces at day 7 that strengthen over time, and reduced force with increased fatigue in the DMD microtissues against the matched control.

myriamed sells myrCell-Skeletal at €750 per million, and is the only supplier in this comparison that will sell you the cells, the casting plate or the finished contractile tissue, all at published prices. The finished tissue route is €1,400 for one, €5,400 for five and €8,000 for twelve, with a seven-to-eleven week order-related manufacturing lead time.

Curi Bio sells the differentiation as a service rather than a vial, and publishes the only phase durations in the category: directed differentiation to myoblasts at 4 to 8 weeks, iPSC expansion and banking at 4 to 6 weeks, CRISPR iPSC editing at 8 to 16 weeks. No prices.

The weakness of this route, stated plainly. Every one of these products sits on a single genetic background per line. If your question is about donor variability, ageing, or a patient-specific response, an iPSC-derived myocyte gives you a clean answer to a question you did not ask. There is also a maturity question that no supplier resolves: the field’s engineered human muscle sits well below adult native tissue on specific force, and choosing an iPSC-derived input does not change that.

Route three: immortalised lines

ATCC C2C12 at $577 is the standard cheap substitute and it is mouse. It differentiates rapidly, forms contractile myotubes and has decades of literature behind it. For method development, device qualification, casting protocol optimisation and technician training — anything where you are validating hardware rather than biology — it is the correct choice and it is what most laboratories should be using while learning to cast tissue. For any claim about human muscle it is not a substitute at any price.

Human immortalised myoblast lines exist and are a genuine third option. Mamchaoui and colleagues published the derivation of immortalised pathological human myoblast lines as a tool for studying neuromuscular disorders, establishing lines from patients across multiple conditions. The scientific argument is strong: an immortalised patient line removes the proliferative ceiling that makes primary myoblasts expensive to scale, while retaining a real patient genotype. The commercial position is weaker — access runs through academic collaboration or an institutional platform rather than a storefront with a published price, and we could not retrieve a public catalogue price for any human immortalised myoblast line during this survey.

The cost of immortalisation. The transformation that removes the proliferative limit is itself a perturbation. Immortalised myoblasts are not primary myoblasts with the clock stopped. If your endpoint touches proliferation, senescence, cell cycle or anything downstream of them, the immortalisation is a confound rather than a convenience.

The specification nobody publishes

Fusion index is the number that matters and it is a release criterion nowhere.

Fusion index — the proportion of nuclei residing in multinucleated myotubes after differentiation — is the standard measure of whether a myoblast preparation will make muscle. It appears constantly in the literature and never on a certificate of analysis.

What suppliers publish instead is a binary. PromoCell routinely checks the capacity to differentiate into multinucleated syncytia for each lot. Cook MyoSite requires every lot to pass a differentiation test before release. Lonza guarantees that HSMM will form multinucleated myotubes, conditional on their media and protocols.

Those are real assurances and better than nothing. They are also not numbers, which means you cannot set an acceptance threshold, cannot compare two lots, and cannot write a specification a supplier can fail. Ask for the lot’s fusion index in writing before purchase, and be prepared for the answer to be that it was not measured.

Three purity markers, three different questions

Purity in this market means at least three distinct things, and a 70 percent figure from one supplier is not comparable to a 90 percent figure from another.

Desmin is an intermediate filament expressed in myogenic cells. Cook MyoSite’s ≥70 percent desmin-positive specification says the population is myogenic. It does not say the cells are proliferation-competent satellite-derived myoblasts rather than partially differentiated cells.

Sarcomeric myosin with negative markers is PromoCell’s approach, and the negative markers are the underrated half. Testing for the absence of smooth muscle α-actin and von Willebrand factor addresses the actual contamination risk in primary muscle culture.

CD56 (NCAM) is the surface marker used for immunomagnetic enrichment of myogenic progenitors. Cook MyoSite’s CD56-positive product at greater than 90 percent purity is the most direct measure of myogenic progenitor content in this comparison, and the only actively selected product we found.

If you are comparing suppliers on purity, first confirm you are comparing the same assay.

What the published force data says about the choice

The Mantarray validation study ran iPSC-derived myogenic cells and primary human myoblasts on the same platform under the same conditions, which makes it the closest thing to a controlled comparison of the two routes.

All values at 1.92 N/m post stiffness in 2 percent horse serum throughout. Do not read this as iPSC-derived being better. Read it as the two routes having different clocks: the iPSC-derived tissues reach their ceiling faster, the primary tissues keep improving over a longer window. If your assay reads out at day 10, those are very different products. If it reads out at day 21, the published data does not tell you which wins.

For context on where either route sits against real muscle: the Duke myobundle work, across ten independent primary cell sources, reported twitch specific force of 2.1 ± 0.9 mN/mm² and tetanic specific force of 7.0 ± 2.2 mN/mm², and the authors state directly that the tetanic value is similar to fetal human muscle and an order of magnitude below adult muscle. That is the honest maturity position of engineered human skeletal muscle from any cell source, and it is not a supplier problem to shop around.

Choosing

Specification checklist

Send this and the quotes become comparable:

• Route: primary, iPSC-derived or immortalised, and the scientific reason for the choice.
• Donor age, sex, BMI and clinical history, and whether you may select the donor.
• Passage number at ship and guaranteed remaining population doublings.
• Purity: which marker, which assay, what threshold, and whether negative markers are tested.
• Fusion index for the specific lot, or an explicit statement that it was not measured.
• Whether every lot passes a differentiation release test.
• Cells per vial, and whether the count is at freeze or viable post-thaw.
• Media required to reach the datasheet performance, and whether any performance guarantee is conditional on using it.
• Sterility, mycoplasma and viral testing panel.
• Whether a matched isogenic or donor-paired control exists for a disease line.
• Total cell mass required for the construct, worked backwards through your expansion doublings.
• Grade: research use only, or phase-appropriate GMP.

Where to go next

Human skeletal myoblasts has the full supplier table with donor disclosure and lot variability notes. 3D skeletal muscle models compared covers what happens after you have the cells, including the post stiffness finding that invalidates most cross-platform force comparisons. Passage number and population doublings explains why the Lonza disclosure matters more than its price.

If you want us to open the quote channel on the quote-gated primary suppliers against a donor specification, or to price the same cell mass across all three routes on one basis, send us the spec.